On March 15, 2024, ThermoGenesis Holdings, Inc. (the "Company") received a conversion notice from Boyalife Group, Inc. ("Boyalife") to convert $1,278,000 of the outstanding principal and $285,000 of the outstanding accrued interest for a total of $1,563,000 of the Second Amended and Restated Convertible Promissory Note issued by the Company to Boyalife on April 16, 2018, as amended by Amendment No 1 dated March 4, 2022, Amendment No 2 dated March 6, 2023 and Amendment No 3 dated January 5, 2024 (as amended, the "Note"). The conversion resulted in the issuance of 4,113,158 shares of the Company's common stock at a conversion price of $0.38 per share. Immediately following the conversion, the outstanding principal and accrued interest of the Note was approximately $6,366,000, and the Company's total outstanding shares were 7,952,780.
2
Attachments
Original Link
Permalink
Disclaimer
Thermogenesis Holdings Inc. published this content on
20 March 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
20 March 2024 10:03:21 UTC.
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.